# Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

> **NCT00004862** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** cytarabine
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00004862
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10
- **Primary completion:** 2001-12
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004862, "Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00004862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*